Getting cancer test results in time for the first treatment decision can make all the difference. New testing options could help more patients get the right treatment from the start.


By Jane Li, vice president and general manager of companion diagnostics at Thermo Fisher Scientific

Progress in precision oncology is usually counted in new therapies, but the number of patients those therapies reach depends on how many are tested and have results in hand while the first treatment decision window is still open. That gives the diagnostic the same weight as the drug in determining who benefits, and it places the clinical laboratory at the center of access.

Non-small cell lung cancer (NSCLC) driven by HER2 mutations shows how much depends on that step. Patients with metastatic disease have historically had few treatment options and a median overall survival of roughly 13 months on first-line standard of care.1 A new therapy can change that outlook, but only for the patients whose mutation is detected and reported in time to shape their first treatment decision.

That connection came into focus in September, when the US Food and Drug Administration (FDA) approved a second companion diagnostic (CDx) for HYRNUO (sevabertinib), Bayer’s targeted therapy for HER2-mutant NSCLC. The Oncomine Dx Express Test on the Genexus Dx System joins the Oncomine Dx Target Test, which was approved alongside the drug in November 2025. Both are validated ways to identify the HER2/ERBB2 tyrosine kinase domain mutations that determine eligibility, and each CDx approval provides laboratories additional testing options that can identify eligible patients.

Testing Results Need to Reach the Care Team in Time

Precision oncology tends to celebrate the therapy. However, a targeted drug only benefits patients who are identified and treated. By some estimates, nearly 50% of eligible patients may miss out on targeted therapies because of testing and reporting delays, access limitations, or lab bottlenecks.2 Those gaps can persist even after guidelines and coverage catch up. A large claims-based cohort study found that biomarker testing remained suboptimal among patients with advanced cancer despite guideline recommendations and broader insurance coverage.3

When a CDx lags behind its therapy, the consequence is that patients who could benefit may not be identified and given access to that treatment. Some eligible patients are never tested, and others receive a standard treatment that is less effective for their disease biology. When the drug and diagnostic reach the market together, labs and clinicians have a clear testing requirement from the first day the therapy is available, which can also support reimbursement.

Much of what determines access happens before a sample is ever sequenced. How a lab allocates scarce tissue across tests and how quickly a specimen moves from biopsy to report both influence whether results are available while treatment decisions are being made.

Another Approved Test for Laboratories

Laboratories differ in testing volume, staffing and the instruments, and access to sequencing expertise. A workflow that fits one laboratory may not fit another. Testing solutions that are automated and flexible in batch sizes can allow more laboratories to provide testing, reducing the reliance on send-out testing and help return timely results. Having another CDx gives laboratories another option as they decide whether to perform testing or send specimens to an outside laboratory. 

The Oncomine Dx Express Test uses an automated NGS workflow on the Genexus Dx System. For laboratories evaluating testing solutions, automation and turnaround time are key operational factors. FDA approval also changes what a lab must do before it can offer a test to patients. An approved in vitro diagnostic can reduce the validation work a lab would take on compared to a laboratory-developed test, which shortens the path to implementation. 

What Local Testing Means for Patients

Community hospitals treat an estimated 80% to 85% of US patients with cancer, yet many still send genomic profiling to outside reference laboratories.4 That can add several critical weeks between the initial biopsy and testing results. In the meantime, some patients begin immunotherapy-chemotherapy in the frontline setting without broad molecular profiling, and a targeted option may be off the table before anyone knew it existed.

Faster, automated sequencing shortens that timeline. In the HYRNUO example, the Oncomine Dx Express Test can return results in as little as 24 hours, which can put genomic results in front of the clinician by the patient’s first follow-up appointment. 

Speed helps only if the specimen holds up, and many tissue samples are small biopsies or fine-needle aspirates or core needle biopsies that may not be feasible for every test. Laboratories evaluating testing solutions must consider specimen requirements alongside turnaround time, panel content, and the needs of the clinical team.

An awareness gap also remains, because some oncologists still assume NGS is slow and available only through centralized labs. Pathologists and laboratory leaders are trusted voices on tumor boards, which puts them in a valuable position to show colleagues what rapid, local testing makes possible and to encourage testing at diagnosis before a treatment is established, so results can inform therapy selection.

Planning for the Next Approval

As more targeted therapies and CDx come, the same limited specimen will make tissue stewardship and test selection more strategic for laboratories. Lab leaders can prepare by treating turnaround time as a core measure of test performance, choosing platforms that are tissue-sparing and multiplexed and working with oncology colleagues to build testing into the earliest steps of care.

A targeted therapy delivers on its promise only when a test result arrives in time to inform therapy selection. Every CDx approval gives laboratories another way to deliver that result, and every lab that can run the test locally brings it closer to the patients who need it.

References:

  1. Waliany S, Nagasaka M, Park L, et al. Real-world prevalence, treatment patterns, and outcomes for patients with HER2 (ERBB2)-mutant metastatic non-small cell lung cancer, from a US-based clinico-genomic database. Cancer Med. 2024;13(24):e70272. 
  2. Sadik H, Pritchard D, Keeling DM, et al. Impact of clinical practice gaps on the implementation of personalized medicine in advanced non-small-cell lung cancer. JCO Precis Oncol. 2022;6:e2200246. 
  3. DaCosta Byfield S, Bapat B, Becker L, et al. Biomarker testing approaches, treatment selection, and cost of care among adults with advanced cancer. JAMA Netw Open. 2025;8(7):e2519963.
  4. Tucker TC, Charlton ME, Schroeder MC, et al. Improving the quality of cancer care in community hospitals. Ann Surg Oncol. 2021;28(2):632-8.
Jane Li

About the author: Jane Li is vice president and general manager of companion diagnostics at Thermo Fisher Scientific, where she leads global strategy to expand the use of NGS in precision oncology.

ID 35719265 © Tyler Olson | Dreamstime.com